1887

n Health SA Gesondheid - Prescribing patterns of methylphenidate in a South African patient population who are members of a private medical aid : research

Volume 10, Issue 4
  • ISSN : 1025-9848
USD

 

Abstract

Metielfenidaat word hoofsaaklik vir aandag-gebrek-hiperaktiwiteitsindroom in kinders gebruik. Die primêre doel van die studie was om die voorskryfpatrone van metielfenidaat van 'n mediese hulpfonds-pasiëntpopulasie in 'n privaatsektor te ondersoek en om die resultate met dié van vorige studies te vergelyk. 'n Studie oor die gebruik van geneesmiddels is uitgevoer. Data is van 'n Suid-Afrikaanse mediese hulpfonds-administreerder verkry. Rekords van voorskrifte vir 2002 van 115 pasiënte wat metielfenidaat ontvang het, is retrospektief ontleed. Bykans 'n driekwart (73.0%) van die pasiënte was mans en 79.1% van die pasiënte was 18 jaar of jonger. Die gemiddelde ouderdom van die pasiënte was 15.6 (SD=10.8) jaar. Sewentien pasiënte was 30 jaar of ouer. Twee-derdes van die voorskrifte (67.3%) was vir metielfenidaat 10 mg (die innoveerderproduk), 20.7% was vir die 20 mg stadig-vrystellende innoveerderproduk en die res was voorskrifte vir die 10 mg generiese ekwivalent wat onlangs bekend gestel is. Pasiënte het gemiddeld 4.0 (SD=3.3) voorskrifte vir metielfenidaat gedurende die jaar ontvang. Die gemiddelde Voorgeskrewe Daaglikse Dosis (VDD) vir metielfeniaat was 15.4 (SD=7.6) mg. Verdere studies word aanbeveel, veral met betrekking tot die lewenskwaliteit van pasiënte vóór en nadat hulle metielfenidaat gebruik het. Die impak van metielfenidaat op die akademiese prestasie van pasiënte behoort ook gekwantifiseer te word. End

Methylphenidate is primarily used for attention deficit hyperactivity disorder (ADHD) in children. The primary aim of the study was to investigate the prescribing patterns of methylphenidate of a medical aid patient population in a private sector and to compare the results with previous studies. An exposure cohort drug utilisation study was conducted. Data were obtained from a South African medical aid administrator. Prescription records for 115 patients who received methylphenidate during 2002 were retrospectively analysed. Nearly three-quarters (73.0%) of the patients were males and 79.1% of patients were 18 years or younger. The average age of patients was 15.6 (SD=10.8) years. Seventeen patients were 30 years or older. Two-thirds of prescriptions (67.3%) were for methylphenidate 10 mg (the innovator product), 20.7% were for the 20 mg slow-release innovator product and the rest were prescriptions for the recently introduced 10 mg generic equivalent tablet. Patients received on average 4.0 (SD=3.3) prescriptions for methylphenidate during the year. The average Prescribed Daily Dose (PDD) for methylphenidate was 15.4 (SD=7.6) mg. Further studies are recommended, especially into the quality of life of patients before and after receiving methylphenidate. The impact of methylphenidate on the academic performance of patients should also be quantified. End

Loading full text...

Full text loading...

Loading

Article metrics loading...

/content/health/10/4/EJC34975
2005-12-01
2016-12-10

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error